GlassScriptPhysician profile
Howard F Preuss, JR.
NPI 1851399448
$1,540.70
in general payments reported to CMS, 2019-2025
25 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $38.14 · 2021: $297 · 2022: $162 · 2023: $321 · 2024: $77.16 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $198.73 | 2023-2025 | Nuzyra |
| Rikco International, LLC | $173.00 | 2019 | |
| Zimmer Biomet Holdings, INC. | $148.32 | 2021 | |
| Misonix INC | $146.87 | 2019 | |
| Epsfl, LLC | $137.46 | 2023 | |
| Organogenesis INC. | $100.65 | 2021-2023 | Puraply |
| Horizon Therapeutics Plc | $96.40 | 2019-2022 | |
| Dynasplint Systems INC. | $71.44 | 2021 | |
| Next Science LLC | $58.15 | 2023-2024 | Blastx, Xperience, Surgx |
| Nabriva Therapeutics, Plc | $49.62 | 2020-2022 | |
| Depuy Synthes Sales INC. | $47.09 | 2022-2023 | Motoband |
| Nevro Corp. | $40.84 | 2022-2023 | Senza |
| Kerecis Limited | $34.43 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic Vascular, INC. | $31.63 | 2019 | |
| Melinta Therapeutics, LLC | $28.58 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $22.84 | 2023 | Collagenase Santyl |
| Bioventus LLC | $21.13 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $20.56 | 2025 | |
| Medartis INC. | $20.11 | 2019 | |
| Abbvie INC. | $19.96 | 2022 | |
| Anika Therapeutics, INC. | $18.14 | 2021 | |
| Averitas Pharma INC. | $16.42 | 2024 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $13.48 | 2022 | |
| Baudax Bio INC. | $13.34 | 2021 | |
| Merck Sharp & Dohme LLC | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Preuss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.